Detalhe da pesquisa
1.
Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001.
Int J Gynecol Cancer
; 32(1): 93-100, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34799418
2.
Immunotherapy in Lung Cancer: Are the Promises of Long-Term Benefit Finally Met?
Adv Exp Med Biol
; 1342: 113-142, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34972964
3.
Argentine consensus recommendations for lung cancer screening programmes: a RAND/UCLA-modified Delphi study.
BMJ Open
; 13(2): e068271, 2023 02 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36737082
4.
Recommendations for detection, prioritization, and treatment of thoracic oncology patients during the COVID-19 pandemic: the THOCOoP cooperative group.
Crit Rev Oncol Hematol
; 153: 103033, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32650215
5.
Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non-Small-Cell Lung Cancer.
Clin Lung Cancer
; 18(1): 50-59, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27856142
6.
Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression.
Oncotarget
; 6(26): 22081-97, 2015 Sep 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-26098779
7.
Age-related genetic abnormalities: the Achilles' heel for customizing therapy in elderly lung cancer patients.
Per Med
; 4(1): 59-72, 2007 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-29793303